Table 3.

Comparison of clinical variables of patients with giant cell arteritis (GCA) with and without femoropopliteal artery involvement.

VariableFemoropopliteal GCANo Evidence for Femoropopliteal GCAp
Patients, no. (%)32 (53.3)28 (46.7)
Age, mean ± SD, yrs66.4 ± 8.269.5 ± 8.80.31
Female, no. (%)26 (81.3)21 (75.0)0.76
Hypertension, no. (%)19 (59.4)21 (75.0)0.27
Diabetes, no. (%)4 (12.5)4 (14.3)1.00
History of smoking, no. (%)12 (37.5)10 (35.7)1.00
Dyslipidemia, no. (%)5 (15.6)8 (28.6)0.35
Headache, no. (%)15 (46.9)19 (67.9)0.12
Jaw claudication, no. (%)8 (25)15 (53.6)0.03
Impaired vision, no. (%)8 (25)12 (42.9)0.18
Arm claudication, no. (%)8 (25.0)6 (21.4)0.77
Leg claudication, no. (%)14 (43.8)3 (10.1)0.01
PMR, no. (%)15 (46.9)9 (32.1)0.30
Constitutional symptoms, no. (%)20 (62.5)17 (60.7)1.00
Time between symptom onset and diagnosis, mean ± SD, wks23.9 ± 23.411.1 ± 11.90.03
Ankle pressures right leg, mean ± SD, mm Hg126 ± 49155 ± 300.01
Ankle pressures left leg, mean ± SD, mm Hg130 ± 46160 ± 35< 0.01
C-reactive protein at time of diagnosis, mean ± SD, mg/dl*7.3 ± 5.96.8 ± 4.70.98
ESR at time of diagnosis, mean ± SD, mm/h**82 ± 3278 ± 380.62
Temporal artery halo (CDS), no. (%)11 (34.4)17 (60.7)0.07
Temporal artery biopsy, no. (%)11 (34.4)17 (60.7)0.07
Positive temporal artery biopsy, no. (%)6 (54.5)12 (70.6)0.44
≥ 3 ACR criteria fulfilled, no, (%)17 (53.1)22 (78.6)0.06
GCA of carotid arteries (CDS), no. (%)15 (48.4)6 (21.4)0.06
GCA of arm arteries (CDS), no. (%)23 (74.2)12 (42.9)0.02
  • * Reference range < 0.5 mg/dl;

  • ** reference range < 20 mm/h. PMR: polymyalgia rheumatica; CDS: color Doppler sonography; ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate.